Treatment for advanced and recurrent endometrial carcinoma: Combined modalities

Oncologist

Volumn 15, Issue 8, 2010, Pages 852-861

  Rauh Hain, J Alejandro ^a   del Carmen, Marcela G ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Chemotherapy; Endometrial cancer; Hormonal therapy; Radiation

Indexed keywords

CARBOPLATIN; CHROMIUM PHOSPHATE; CISPLATIN; CYCLOPHOSPHAMIDE; DEFOROLIMUS; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; ETOPOSIDE; EVEROLIMUS; FLUOROURACIL; GESTAGEN; HYDROXYPROGESTERONE CAPROATE; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MEDROXYPROGESTERONE; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; MELPHALAN; METHOTREXATE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE RECEPTOR; PROTEIN KINASE B; TAMOXIFEN; TEMSIROLIMUS; TRASTUZUMAB; UNINDEXED DRUG;

ABDOMINAL RADIOTHERAPY; ARTICLE; BRACHYTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DISEASE FREE SURVIVAL; DRUG INTERMITTENT THERAPY; DRUG TARGETING; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; FEMALE; GASTROINTESTINAL DISEASE; HEALTH STATUS; HORMONAL THERAPY; HUMAN; LAPAROSCOPIC SURGERY; LYMPH NODE METASTASIS; MEDICAL DECISION MAKING; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PARAAORTIC LYMPH NODE; PATIENT SELECTION; PELVIS EXENTERATION; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROGNOSIS; SECOND LOOK SURGERY; TUMOR VOLUME; UTERUS SURGERY;

COMBINED MODALITY THERAPY; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING;

EID: 77956819536     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0091     Document Type: Article

References (78)

1. Tarone RE, Chu KC. Age-period-cohort analyses of breast-, ovarian-, endometrial-, and cervical-cancer mortality rates for Caucasian women in the USA. J Epidemiol Biostat 2000;5:221-231.
2. Morgan JD 3rd, Reddy S, Sarin P et al. Isolated vaginal recurrences of endometrial carcinoma. Radiology 1993;189:609-613.
3. Hoekstra CJ, Koper PC, van Putten WL. Recurrent endometrial adenocarcinoma after surgery alone: Prognostic factors and treatment. Radiother Oncol 1993;27:164-166.
4. Creutzberg CL, van Putten WL, Koper PC et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: Multicenter randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 2000;355: 1404-1411.
5. Creutzberg CL, van Putten WL, Koper PC et al. Survival after relapse in patients with endometrial cancer: Results from a randomized trial. Gynecol Oncol 2003;89:201-209.
6. Kuten A, Grigsby PW, Perez CA et al. Results of radiotherapy in recurrent endometrial carcinoma: A retrospective analysis of 51 patients. Int J Radiat Oncol Biol Phys 1989;17:29-34.
7. Curran WJ Jr, Whittington R, Peters AJ et al. Vaginal recurrences of endometrial carcinoma: The prognostic value of staging by a primary vaginal carcinoma system. Int J Radiat Oncol Biol Phys 1988;15:803-808.
8. Pai HH, Souhami L, Clark BG et al. Isolated vaginal recurrences in endometrial carcinoma: Treatment results using high-dose-rate intracavitary brachytherapy and external beam radiotherapy. Gynecol Oncol 1997;66: 300-307.
9. Jhingran A, Burke TW, Eifel PJ. Definitive radiotherapy for patients with isolated vaginal recurrence of endometrial carcinoma after hysterectomy. Int J Radiat Oncol Biol Phys 2003;56:1366-1372.
10. Jereczek-Fossa B, Badzio A, Jassem J. Recurrent endometrial cancer after surgery alone: Results of salvage radiotherapy. Int J Radiat Oncol Biol Phys 2000;48:405-413.
11. Wylie J, Irwin C, Pintilie M et al. Results of radical radiotherapy for recurrent endometrial cancer. Gynecol Oncol 2000;77:66-72.
12. Monk BJ, Tewari KS, Puthawala AA et al. Treatment of recurrent gynecologic malignancies with iodine-125 permanent interstitial irradiation. Int J Radiat Oncol Biol Phys 2002;52:806-815.
13. Nag S, Yacoub S, Copeland LJ et al. Interstitial brachytherapy for salvage treatment of vaginal recurrences in previously unirradiated endometrial cancer patients. Int J Radiat Oncol Biol Phys 2002;54:1153-1159.
14. Tewari K, Cappuccini F, Brewster WR et al. Interstitial brachytherapy for vaginal recurrences of endometrial carcinoma. Gynecol Oncol 1999;74: 416-422.
15. Potish RA, Twiggs LB, Adcock LL et al. Role of whole abdominal radiation therapy in the management of endometrial cancer: Prognostic importance of factors indicating peritoneal metastases. Gynecol Oncol 1985;21: 80-86.
16. Potish RA, Twigs LB, Adcock LL et al. Paraaortic lymph node radiotherapy in cancer of the uterine corpus. Obstet Gynecol 1985;65:251-256.
17. Feuer GA, Calanog A. Endometrial carcinoma: Treatment of positive paraaortic nodes. Gynecol Oncol 1987;27:104-109.
18. Bristow RE, Zerbe MJ, Rosenshein NB et al. Stage IVB endometrial carcinoma: The role of cytoreductive surgery and determinants of survival. Gynecol Oncol 2000;78:85-91.
19. Chi DS, Welshinger M, Venkatraman ES et al. The role of surgical cytoreduction in stage IV endometrial carcinoma. Gynecol Oncol 1997;67:56-60.
20. Goff BA, Goodman A, Muntz HG et al. Surgical stage IV endometrial carcinoma: A study of 47 cases. Gynecol Oncol 1994;52:237-240.
21. Morley GW, Hopkins MP, Lindenauer SM et al. Pelvic exenteration, University of Michigan: 100 patients at 5 years. Obstet Gynecol 1989;74:934-943.
22. Barakat RR, Goldman NA, Patel DA et al. Pelvic exenteration for recurrent endometrial cancer. Gynecol Oncol 1999;75:99-102.
23. Dowdy SC, Mariani A, Cliby WA et al. Radical pelvic resection and intraoperative radiation therapy for recurrent endometrial cancer: Technique and analysis of outcomes. Gynecol Oncol 2006;101:280-286.
24. Scarabelli C, Campagnutta E, Giorda G et al. Maximal cytoreductive surgery as a reasonable therapeutic alternative for recurrent endometrial carcinoma. Gynecol Oncol 1998;70:90-93.
25. Campagnutta E, Giorda G, De Piero G et al. Surgical treatment of recurrent endometrial carcinoma. Cancer 2004;100:89-96.
26. Bristow RE, Santillan A, Zahurak ML et al. Salvage cytoreductive surgery for recurrent endometrial cancer. Gynecol Oncol 2006;103:281-287.
27. Soper JT, Creasman WT, Clarke-Pearson DL et al. Intraperitoneal chromic phosphate P 32 suspension therapy of malignant peritoneal cytology in endometrial carcinoma. Am J Obstet Gynecol 1985;153:191-196.
28. Creasman WT, Disaia PJ, Blessing J et al. Prognostic significance of peritoneal cytology in patients with endometrial cancer and preliminary data concerning therapy with intraperitoneal radiopharmaceuticals. Am J Obstet Gynecol 1981;141:921-929.
29. Yazigi R, Piver MS, Blumenson L. Malignant peritoneal cytology as prognostic indicator in stage I endometrial cancer. Gynecol Oncol 1983;62: 359-362.
30. Rose PG, Bundy BN, Watkins EB et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999;340:1144-1153.
31. Peters WA 3rd, Liu PY, Barrett RJ 2nd et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000;18:1606-1613.
32. Pickel H, Lahousen M, Petru E et al. Consolidation radiotherapy after carboplatin- based chemotherapy in radically operated advanced ovarian cancer. Gynecol Oncol 1999;72:215-219.
33. Duska LR, Berkowitz R, Matulonis U et al. A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuGCSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer. Gynecol Oncol 2005;96:198-203.
34. Soper JT, Reisinger SA, Ashbury R et al. Feasibility study of concurrent weekly cisplatin and whole abdominopelvic irradiation followed by doxorubicin/ cisplatin chemotherapy for advanced stage endometrial carcinoma: A Gynecologic Oncology Group trial. Gynecol Oncol 2004;95:95-100.
35. Bruzzone M, Miglietta L, Frazone P et al. Combined treatment with chemotherapy and radiotherapy in high-risk FIGO stage III-IV endometrial cancer patients. Gynecol Oncol 2004;93:345-352.
36. Frigerio L, Mangili G, Aletti G et al. Concomitant radiotherapy and paclitaxel for high-risk endometrial cancer: First feasibility study. Gynecol Oncol 2001;81:53-57.
37. Greven K, Winter K, Underhill K et al. Preliminary analysis of RTOG 9708: Adjuvant postoperative radiotherapy combined with cisplatin/paclitaxel chemotherapy after surgery for patients with high-risk endometrial cancer. Int J Radiat Oncol Biol Phys 2004;59:168-173.
38. Randall ME, Filiaci VL, Muss H et al. Randomized phase III trial of wholeabdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 2006;24:36-44.
39. Fleming GF. Major progress for a less common cancer. J Clin Oncol 2006; 24:6-8.
40. Kohorn EI. Gestagens and endometrial carcinoma. Gynecol Oncol 1976;4: 398-411.
41. Kauppila A. Progestin therapy of endometrial, breast, and ovarian carcinoma. A review of clinical observations. Acta Obstet Gynecol Scand 1984; 63:441-450.
42. Kelley RM, Baker WH. Progestational agents in the treatment of carcinoma of the endometrium. N Engl J Med 1961;264:216-222.
43. Piver MS, Barlow JJ, Luain JR et al. Medroxyprogesterone acetate versus hydroxyprogesterone caproate in women with metastatic endometrial adenocarcinoma. Am J Clin Oncol 1980;45:268-272.
44. Bonte J. Medroxyprogesterone in the management of primary and recurrent or metastatic uterine adenocarcinoma. Acta Obstet Gynecol Scand Suppl 1972;19:21-24.
45. Reifenstein EC Jr. The treatment of advanced endometrial cancer with hydroxyprogesterone caproate. Gynecol Oncol 1974;2:377-414.
46. Geisler HE. The use of megestrol acetate in the treatment of advanced malignant lesions of the endometrium. Gynecol Oncol 1979;1:340-346.
47. Thigpen JT, Brady MF, Alvarez RD et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: A dose-response study by the Gynecologic Oncology Group. J Clin Oncol 1999;17:1736-1744.
48. Quinn MA, Cauchi M, Fortune D. Endometrial carcinoma: Steroid receptors and response to medroxyprogesterone acetate. Gynecol Oncol 1985; 21:314-319.
49. Thigpen JT, Blessing J, Disaia P. Oral medroxyprogesterone acetate in advanced or recurrent endometrial carcinoma: Results of therapy and correlation with estrogen and progesterone receptor levels. In: Iacobelli S, ed. Endocrinology and Malignancy: Basic and Clinical Issues, The Proceedings of the First International Congress on Cancer and Hormones. Rome: CRC Press, Parthenon Publishers, 1986:446-447.
50. Barakat RR, Grigsby PW, Sabbatini P et al. Corpus epithelial tumors. In: Hoskins WJ, Perez CA, Young RC, eds. Principles and Practices of Gynecologic Oncology, Second Edition. Philadelphia: Lippincott-Raven, 1997: 880-884.
51. Mortel R, Levy C, Wolff JP et al. Female sex steroid receptors in postmenopausal endometrial carcinoma and biochemical response to an antiestrogen. Cancer Res 1981;41:1140-1147.
52. Carlson JA Jr, Allegra JC, Day TG Jr et al. Tamoxifen and endometrial carcinoma: Alterations in estrogen and progesterone receptors in untreated patients and combination hormonal therapy in advanced neoplasia. Am J Obstet Gynecol 1984;149:149-153.
53. Thigpen T, Brady MF, Homesley HD et al. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 2001;19:364-367.
54. Moore TD, Phillips PH, Nerenstone SR et al. Systemic treatment of advanced and recurrent endometrial carcinoma: Current status and future directions. J Clin Oncol 1991;9:1071-1088.
55. Decruze SB, Green JA. Hormone therapy in advanced and recurrent endometrial cancer: A systematic review. Int J Gynecol Cancer 2007;17:964-978.
56. Lentz SS, Brady MF, Major FJ et al. High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol 1996;14:357-361.
57. Pandya KJ, Yeap BY, Weiner LM et al. Megestrol and tamoxifen in patients with advanced endometrial cancer: An Eastern Cooperative Oncology Group study (E4882). Am J Clin Oncol 2001;24:43-46.
58. Fiorca JV, Brunetto VL, Hanjani P et al. A phase II study of recurrent and advanced endometrial carcinoma treated with alternating courses of megestrol acetate (Megace) and tamoxifen citrate (Nolvadex) [abstract 1499]. Proc Am Soc Clin Oncol 2000;19.
59. Whitney CW, Brunetto VL, Zaine RJ et al. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2004;92:4-9.
60. Horton J, Elson P, Gordon P et al. Combination chemotherapy for advanced endometrial cancer. An evaluation of three regimens. Cancer 1982;49: 2441-2445.
61. Piver MS, Lele SB, Patsner B et al. Melphalan, 5-fluorouracil, and medroxyprogesterone acetate in metastatic endometrial carcinoma. Obstet Gynecol 1986;67:261-267.
62. Cohen CJ, Bruckner HW, Deppe G et al. Multidrug treatment of advanced and recurrent endometrial carcinoma: A Gynecologic Oncology Group study. Obstet Gynecol 1984;63:719-726.
63. Ayoub J, Audet-Lapointe P, Méthot Y et al. Efficacy of sequential cyclical hormonal therapy in endometrial cancer and its correlation with steroid hormone receptor status. Gynecol Oncol 1988;31:327-337.
64. Cornelison TL, Baker TR, Piver MS et al. Cisplatin, adriamycin, etoposide, megestrol acetate versus melphalan, 5-fluorouracil, medroxyprogesterone acetate in the treatment of endometrial carcinoma. Gynecol Oncol 1995;59: 243-248.
65. Bafaloukos D, Aravantinos G, Samonis G et al. Carboplatin, methotrexate and 5-fluorouracil in combination with medroxyprogesterone acetate (JMF-M) in the treatment of advanced or recurrent endometrial carcinoma: A Hellenic Cooperative Oncology Group study. Oncology 1999;56:198-201.
66. Santin AD, Bellone S, Gokden M et al. Overexpression of HER-2/neu in uterine serous papillary cancer. Clin Cancer Res 2002;8:1271-1279.
67. Grushko TA, Filiaci VL, Mundt AJ et al. An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2008;108:3-9.
68. Villella JA, Cohen S, Smith DH et al. HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications. Int J Gynecol Cancer 2006;16:1897-1902.
69. Odicino FE, Bignotti E, Rossi E et al. HER-2/neu overexpression and amplification in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization. Int J Gynecol Cancer 2008; 18:14-21.
70. Fleming GF, Sill MW, Darcy KM et al. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2010;116:15-20.
71. Mutter GL, Lin MC, Fitzgerald JT et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 2000;92:924-930.
72. Lax SF, Kendall B, Tashiro H et al. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: Evidence of distinct molecular genetic pathways. Cancer 2000;88: 814-824.
73. Fukuchi T, Sakamoto M, Tsuda H et al. Beta-catenin mutation in carcinoma of the uterine endometrium. Cancer Res 1998;58:3526-3528.
74. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002;296: 1655-1657.
75. Oza AM, Elit L, Biagi J et al. Molecular correlates associated with a phase II study of temsirolimus (CCI-779) in patients with metastatic or recurrent endometrial cancer. NCIC IND 160. Proc Am Soc Clin Oncol 2006;24(18 suppl):3003.
76. Colombo N, McMeekin P, Schwartz J et al. A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer. Proc Am Soc Clin Oncol 2007;25:(18 suppl):5516.
77. Slomovitz B, Burke T, Lu K et al. Loss of PTEN expression associated with response to RAD001 (mTOR inhibitor) in patients with recurrent endometrial cancer: Translational evaluation from a phase II study [abstract 62]. Presented at the 38th Annual Meeting on Women's Cancer, San Diego, CA, March 3-7, 2007.
78. Gallion HH, Brunetto VL, Cibull M et al. Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 2003; 21:3808-3813.